EICHORPublic-registry site landscape for NCT02851849, “A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus”, a Type 2 Diabetes Mellitus study sponsored by Ligand Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02851849 (registry record) |
| Study title | A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus |
| Sponsor | Ligand Pharmaceuticals |
| Condition(s) | Type 2 Diabetes Mellitus |
| Phase | PHASE2 |
| Listed sites | 29 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02851849.
Eichor generates a preliminary site-risk snapshot for NCT02851849 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Type 2 Diabetes Mellitus trials
← Eichor home · All tracked trials · Type 2 Diabetes Mellitus studies · Weekly briefs
